BRIEF-Relmada Therapeutics To Discontinue The Reliance Ii And Relight Phase 3 Studies Of Rel-1017

Reuters
2024-12-09
BRIEF-Relmada <a href="https://laohu8.com/S/LENZ">Therapeutics</a> To Discontinue The Reliance Ii And Relight Phase 3 Studies Of Rel-1017

Dec 9 (Reuters) - Relmada Therapeutics RLMD.O:

  • RELMADA THERAPEUTICS TO DISCONTINUE THE RELIANCE II AND RELIGHT PHASE 3 STUDIES OF REL-1017

  • RELMADA THERAPEUTICS INC: WILL CONTINUE TO ADVANCE PHASE 1 STUDY OF REL-P11, AN INVESTIGATIONAL AGENT FOR TREATMENT OF METABOLIC DISEASE

  • RELMADA THERAPEUTICS INC: TO EXPLORE STRATEGIC ALTERNATIVES

Source text: ID:nGNX8RxPyd

Further company coverage: RLMD.O

((Reuters.Briefs@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10